Microbiota and Metabolomics of Intestinal Type of Gastric Cancer
NCT ID: NCT06079554
Last Updated: 2024-04-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
32 participants
OBSERVATIONAL
2024-03-31
2025-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Immunological Heterogeneity of Tumor Microenvironment in the Prognosis of Gastric Cancer
NCT04819958
Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy
NCT06202781
A Multi-omics-based Metabolic Typing Study of Gastric Cancer
NCT06134011
First-Line and Neoadjuvant Immunotherapy for Gastric Cancer
NCT06727981
Plasma Metabolic Biomarkers for Gastric Cancer Diagnosis
NCT06109805
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
the gastric cancer group
16 cases of intestinal type of gastric cancer under the background of atrophic gastritis
No interventions assigned to this group
the atrophic gastritis group
16 cases of atrophic gastritis without gastric cancer matched according to gender, age, and degree of gastric atrophy
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Underwent Endoscopic submucosal dissection（ESD）
Exclusion Criteria
* have severe systemic inflammatory disease ,serious illness such as diabetes, chronic lung diseases
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jilin University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dong Yang
Assisted Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
the First Hospital of Jilin University
Changchun, Jilin, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Dong Yang, doctor
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Dong Yang, Master
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
130027
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.